NCT02728206View on ClinicalTrials.gov

Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation

PHASE2CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

June 12, 2016

Primary Completion Date

January 16, 2018

Study Completion Date

January 16, 2018

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

SOF/VEL

400/100 mg FDC tablet administered orally once daily

Trial Locations (1)

Unknown

Auckland

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY